Advanced Enzyme Tech (AETL), a leading enzyme-focused company, has reported a robust financial performance for the first quarter of FY26. The company's consolidated revenue and profit saw significant year-over-year increases, reflecting strong operational efficiency and market demand for its products.

Financial Highlights

• Consolidated revenue stood at ₹1,859.00 million, up 20% from ₹1,545.00 million in Q1 FY25.
• EBITDA grew 10% to ₹564.00 million.
• Consolidated net profit increased 16% to ₹404.00 million, compared to the same quarter last year.
• EBITDA margin stood at 30.00% and PAT margin at 22.00%.

Segment Performance

Geographical Performance

Operational Performance

The company's performance demonstrates its ability to maintain growth momentum across various sectors. The increase in revenue suggests strong demand for AETL's enzyme products, particularly in human and animal nutrition segments.

Strategic Focus

AETL maintains focus on:

• Expanding its product portfolio in probiotics
• Growing its human nutrition B2C business through the Wellfa brand
• Developing bio-catalysis solutions for API manufacturers

Future Outlook

Advanced Enzyme Tech's strong start to the quarter positions it well for continued success in the enzyme market. The company's focus on innovation and strategic investments in key segments is likely to support its growth trajectory in the coming periods.

Note: All financial figures are in Indian Rupees (INR).

Advanced Enzyme Tech has announced a significant green energy initiative through its subsidiary, JC Biotech Private Limited. The move marks a step towards sustainable operations in the enzyme industry.

Collaboration for Solar Power

JC Biotech, a 95.72% subsidiary of Advanced Enzyme Tech, has approved a collaboration with Raywatt Solar Power Systems Private Limited. This partnership aims to develop a group captive solar power project to meet the electricity requirements of JC Biotech's plant located at APIIC Growth Centre, Gundlapalli Village, Ongole, Andhra Pradesh.

Investment in Green Energy

As part of this collaboration, JC Biotech will invest in 26% equity shares of a Special Purpose Vehicle (SPV) company to be set up for this project. The total investment is expected to be up to ₹10.00 million through cash consideration. This investment aligns with regulatory requirements for group captive power projects.

Strategic Benefits

The move is anticipated to provide JC Biotech with a sustainable and cost-effective power source for its operations. By transitioning to solar energy, the company aims to reduce its carbon footprint and potentially lower long-term energy costs.

Project Timeline

The project completion is expected by March 31, 2026. This strategic investment is expected to make the target entity an associate company of JC Biotech upon completion.

Regulatory Aspects

It's worth noting that no governmental or regulatory approvals are required for this investment amount, streamlining the process for JC Biotech.

This green energy initiative by JC Biotech underscores Advanced Enzyme Tech's commitment to sustainable practices in the enzyme industry, marking a significant step towards eco-friendly operations and energy efficiency.